Clinical Trials Logo

Tissue Expansion clinical trials

View clinical trials related to Tissue Expansion.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05975372 Not yet recruiting - Tissue Expansion Clinical Trials

Blossom® Smart Expander Device for Tissue Expander/Implant-Based Breast Reconstruction

Start date: September 2023
Phase: N/A
Study type: Interventional

The conventional breast tissue expander used for breast reconstruction/ augmentation requires weekly or biweekly injections of saline through the skin and into an integrated port in the implant using a needle and syringe in order to expand breast skin, which is an in-office procedure and can be uncomfortable for patients. Blossom Smart Expander Technology, currently available on the market, aims to achieve the same tissue expansion while avoiding frequent injections through the skin by means of an expansion device that slowly and continuously injects a very small amount of saline. Expansion of the device is based on pressure and volume in the expander, allowing for a tailored expansion process for individual patients' physiology. The purpose of this study is to assess the clinical effectiveness of Blossom Smart Expander Technology in 2-staged tissue expander/implant-based breast reconstruction/ augmentation compared to standard tissue expansion methods.

NCT ID: NCT04781907 Not yet recruiting - Clinical trials for Breast Reconstruction

Patient Performed Tissue Expansion for Two-stage Alloplastic Breast Reconstruction

Start date: June 2024
Phase: N/A
Study type: Interventional

This study is designed to evaluate the feasibility and safety of patient performed tissue expansions in two-stage alloplastic breast reconstruction with tissue expanders. The investigators hypothesize that a motivated patient who learns and demonstrates proper technique can safely perform tissue expansions at home, with no increase in complications or problems with reconstruction. 30 participants will be recruited for this study, 10 into a Home Expansion Group, and 20 into a Control Group.